Dr. Rahul Parikh, Radiation Oncologist at Mount Sinai Beth Israel and Mount Sinai Hospital, in New York
Stations, the following is a news announcement. Suggested lead in 3, 2, 1…
(INTRO)
More than 11,000 of the world’s top cancer doctors and scientists gathered at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO) at the Moscone Center in San Francisco. This year’s theme for the four-day event, September 14-17, was “Targeting Cancer: Technology & Biology” and highlighted how technology and biology advance the field and improve patient outcomes and quality of life.
Dr. Rahul Parikh, a radiation oncologist at Mount Sinai Beth Israel and Mount Sinai Hospital, in New York, discusses his study on the effects of radiation therapy on patients with Hodgkin’s Disease.
(PARIKH)
OUR STUDY WAS FOCUSED ON PATIENTS WITH EARLY STAGE HODGKIN’S DISEASE AND WE FOUND THAT THERE WAS A SIGNIFICANT OVERALL SURVIVal BENEFIT WHEN RADIATION THERAPY WAS INCORPORATED INTO THE TREATMENT REGIMENT. sO AS A GROUP, WE RECOMMEND THAT RADIATION THERAPY REMAIN STANDARD PRACTICE WITHIN THE COMBINED MODALITY THERAPY APPROACH FOR THE PATIENTS WITH EARLY STAGE HODGKIN’S DISEASE.
(CLOSE)
For more information, visit www.astro.org.